

## Review Form 1.6

Journal Name:	Asian Journal of Pediatric Research
Manuscript Number:	Ms_AJPR_84920
Title of the Manuscript:	Further review of aspirin in the treatment of Kawasaki disease
Type of the Article	

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajpr.com/index.php/AJPR/editorial-policy> )

### PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ul style="list-style-type: none"> <li>No referencing within the introduction.</li> <li>The intro is very poorly written, disjointed and often repetitive.</li> <li>No real mention of the epidemiology of Kawasaki</li> <li>You do not mention skin desquamation in clinical manifestation and the characteristics of the fever being &gt;5d and the triphasic nature of the disease</li> <li>Complete v incomplete KD is something you should explore</li> <li>I do not think the metabolism and availability section adds anything to the manuscript</li> </ul> <p>Similarities and differences of aspirin tolerance and toxic and side effects between European and American races and Asian people</p> <ul style="list-style-type: none"> <li>I think a restructure of this entire manuscript is needed. A lot of superfluous and irrelevant information is presented.</li> <li>References are not correctly written</li> </ul>	
<b>Minor</b> REVISION comments	<ul style="list-style-type: none"> <li>Aspirin was first used to Anti-rheumatism medicine in the 1960s and 1970s (100~150mg), and then it became anti-inflammatory and anti-thrombotic ---please alter it had all these properties but at different stages was indicated and prescribed for different reasons.</li> <li>http://BAYER.CO's company – a bit shocked this was thought to be ok</li> <li>Please define by how much IVIg assist in aneurysmal complications</li> <li>Please remove 1). 2) 3)</li> <li>Please alter sentence main therapeutic objectives. Poorly written</li> </ul>	
<b>Optional/General</b> comments		

### PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

### Reviewer Details:

Name:	Dominic Adam Worku
Department, University & Country	University Hospital of Wales, United Kingdom